|Traded as||LSE: DPH|
|Tony Rice, (Chairman)|
Ian Page, (CEO)
|Revenue||£407.1 million (2018)|
|£99.2 million (2018)|
|£36.1 million (2018)|
The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists. It was first listed on the London Stock Exchange in 2000. In 2007 it bought VetXX, a Danish veterinary products business, for £62m. It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.
The Company sells pharmaceuticals - mainly for dogs, cats, equine and food producing animals; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.
- "Annual Report 2018". Dechra Pharmaceuticals. Retrieved 17 March 2019.
- Montague Private Equity announces sale of VetXX
- "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015.
- "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
- "Dechra Pharmaceuticals PLC". dechraplc.com. Retrieved 28 March 2015.
|This article about an English company is a stub. You can help Wikipedia by expanding it.|